Skip to main content
Premium Trial:

Request an Annual Quote

Theradiag, French Cancer Institute Partner to Assess Pharmacogenomic Value of miRNA

NEW YORK (GenomeWeb News) – Theranostics and in vitro diagnostics firm Theradiag today announced a partnership with the Regional Cancer Institute of Montpellier in France to assess the role of microRNA in predicting response to therapies for colorectal cancer.

The partners will develop theranostic tools for the screening and monitoring of colorectal cancer as part of the deal, which aims to evaluate the expression and predictive role of miRNA in treatment response to radio- and chemotherapies for the disease. Theradiag will identify biomarkers that may be developed into theranostic assays, the partners said.

Financial and other terms of the deal were not disclosed.

Theradiag also announced that it opened a new laboratory dedicated to applied research for the development of miRNA-based assays within the Cap Alpha incubator in Montpellier.

Theradiag bought miRNA-based technology firm Prestizia a year ago.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.